Introduction
Aurora-A kinase is an important member of the family of aurora kinases that play essential roles in mitotic events. Regulation of the steady-state levels of Aurora-A is very important as higher levels of Aurora-A in human and rodent cells induce centrosome amplification, aneuploidy, transformed phenotype and tumor formation in nude mice (Bischoff et al., 1998; Zhou et al., 1998) . Aurora-A is overexpressed in many cancer types and mapped to chromosome 20q13 region, which is frequently amplified in many human cancers (Tanaka et al., 1999; Gritsko et al., 2003; Li et al., 2003) . Overexpression of Aurora-A significantly correlates with the induction of aneuploidy, centrosome anomaly, poor prognosis and invasiveness of the primary human tumors and of experimental tumors in animal model systems (Sakakura et al., 2001; Buschhorn et al., 2005) . Aurora-A levels and functions are regulated by multiple mechanisms such as gene amplification, transcription, post-translational modifications including phosphorylation/dephosphorylation and proteolysis through proteasome-dependent pathway (Honda et al., 2000; Walter et al., 2000) . Aurora-A represents one of the many mitotic proteins, whose protein levels are temporally regulated by the Ub-dependent proteolysis at the end of mitosis before cells progress into subsequent G 1 phase. Aurora-A is ubiquitinated by the Cdh1-activated anaphase-promoting complex/cyclosome (APC/C), an E3 ubiquitin (Ub) ligase through the recognition of C-terminal destruction box (D-box) and N-terminal A-box. It has been proposed that dephosphorylation of the highly conserved S 51 in A-box during mitotic exit could control the timing of Aurora-A degradation (Honda et al., 2000; Littlepage and Ruderman, 2002; Taguchi et al., 2002) .
Antizyme (Az) represents one of the important classes of evolutionarily conserved proteins that regulate cell growth and metabolism. It is involved in the Ubindependent protein degradation and small molecule transport (Gerner and Meyskens, 2004) . Az expression is induced by an unusual polyamine-dependent mechanism in which a programmed þ 1 frame-shift occurs during translation of the Az mRNA leading to the expression of full-length and functional Az protein (Ivanov et al., 2000) . Once expressed, Az binds and inhibits ornithine decarboxylase (ODC), a rate-limiting enzyme in polyamine biosynthesis, and targets it for degradation through Ub-independent pathway (Rom and Kahana, 1994) . Increased polyamines and ODC activities are associated with many human malignancies (Gerner and Meyskens, 2004) . As a negative regulator of ODC and thus polyamine levels, overexpression of Az leads to cell-cycle arrest, apoptosis (Iwata et al., 1999; Koike et al., 1999) and inhibition of tumor growth in in vivo mouse models (Feith et al., 2001; Fong et al., 2003) . Az increases ODC degradation by enhancing ODC association with proteasome, rather than accelerating the rate of proteasomal processing (Zhang et al., 2003) . The attachment of Az causes conformational changes in ODC, thereby exposing its C-terminal degradation signal for recognition by 26S proteasome (Li and Coffino, 1993) . Unlike Ub, Az is usually spared from destruction and released from the ODCAz complex at the proteasome (Murakami et al., 1992) . Therefore, a single Az molecule can catalyze multiple rounds of ODC degradation. Studies in vitro and in vivo (Glass and Gerner, 1987; Rosenberg-Hasson et al., 1989) have revealed that this Az-mediated protein degradation process is essentially Ub-independent. Recent studies have demonstrated that Az can bind other proteins (Lin et al., 2002; Newman et al., 2004) besides ODC and facilitate their degradation through Ub-independent pathway.
Earlier, we identified AURKAIP1 (Kiat et al., 2002) , an Aurora-A kinase interacting protein, which is involved in the degradation of Aurora-A through proteasome-dependent pathway. Further studies on the AURKAIP1-dependent degradation of Aurora-A revealed that there exists an alternative Ub-independent pathway for Aurora-A degradation and AURKAIP1 promotes Aurora-A degradation through this Ub-independent yet proteasome-dependent pathway (Lim and Gopalan, 2007) . However, the mechanism underlying the targeting of Aurora-A to the proteasome in the absence of ubiquitination remains unexplored. As Az is known to play a role in Ub-independent targeting of a few substrates other than ODC, we investigated whether Az1, a well-studied member of the Az family, could mediate Ub-independent degradation of Aurora-A. Here, we present that Az1 can interact with Aurora-A and target it for degradation through proteasome-dependent but Ub-independent pathway. AUR-KAIP1 enhances the binding of Az1 to Aurora-A and promotes recognition and targeting of Aurora-A to proteasome in the absence of ubiquitination.
Results

Az1 targets Aurora-A for proteasomal degradation
Previous studies showed that Aurora-A could be degraded through proteasome-dependent pathway in the absence of ubiquitination (Lim and Gopalan, 2007) . To provide a mechanistic explanation for how Aurora-A is targeted in the absence of ubiquitination, we studied Az1, an established player in Ub-independent proteasomal targeting. To begin with, we investigated whether Az1 can downregulate Aurora-A. Coexpression of Aurora-A and Az1 led to decreased steady-state levels of transfected Aurora-A in both human epithelial cells from cervical carcinoma (HeLa) and Chinese hamster ovary (CHO) cells (Figure 1a) . The steady-state levels of ODC, a well-documented target of Az1, were also decreased when coexpressed with Az1, verifying the reliability of the assay (Supplementary Figure 1a) . As the Az1-mediated drop in Aurora-A levels were followed with ectopically expressed Aurora-A whose expression is driven by cytomegalovirus (CMV) promoter, the involvement of transcriptional mechanisms could be ruled out. Thus, the decrease in the steady-state levels of Aurora-A observed in the presence of Az1 is mainly post-transcriptional. To test whether overexpression of Az1 has any effect on the stability of endogenous Aurora-A, HeLa cells were transfected with Az1 and the Aurora-A stability in vivo was followed. The results obtained indicated that overexpression of Az1 augmented decrease in the levels of endogenous Aurora-A protein with comparable efficiency. Endogenous cyclinB1 was not affected by the expression of Az1, while cyclinD1, a reported Az1 target was downregulated ( Figure 1b ). Exogenous addition of polyamines has been shown to upregulate the synthesis of functional Az1 through the unique translational frame-shift mechanism (Rom and Kahana, 1994) . To verify whether higher endogenous levels of Az1 will have a similar effect on Aurora-A, AT2.1 prostate carcinoma cells were treated with 10 mM putrescine to stimulate Az1 expression and Aurora-A levels were monitored. As shown in Figure 1c , higher endogenous levels of Az1 could downregulate both Aurora-A and cyclinD1, while cyclinA was spared. To demonstrate that the effect of Az1 on Aurora-A levels is indeed the degradation of Aurora-A through the proteasome-dependent pathway, Az1 and Aurora-A were coexpressed in HeLa cells in the presence of proteasome inhibitors MG132 or lactacystin and the levels of Aurora-A was followed. Treatment with proteasome inhibitors restored the Az1-mediated loss of both transfected (Figure 1d ) as well as endogenous (Figure 1e ) Aurora-A, suggesting that Az1 targets Aurora-A through a proteasome-dependent pathway. It has been demonstrated that Az1 is capable of degrading its substrates in vitro in reticulocyte lysates, a rich source of proteasome. To demonstrate Az1-mediated downregulation of Aurora-A in vitro, degradation assays were performed in vitro in reticulocyte lysates as the source of proteasome. Az1 and Aurora-A proteins were synthesized separately in an in vitro coupled transcription/translation system and incubated together in the presence of an ATP-regenerating system. Wildtype Aurora-A has been shown to be less stable in reticulocyte lysate presumably due to the presence of low levels of cdh1 in the lysates, which could target Aurora-A for degradation through proteasome-dependent pathway (Crane et al., 2004) . Hence, a stable A-box mutant of Aurora-A, which is recalcitrant to cdh1-mediated degradation, was used in the in vitro degradation assays. Preliminary studies using this A-box mutant and Az1 proteins showed that both proteins are relatively more stable in the lysates under the assay conditions. However, when combined together, Az1 led to lower levels of Aurora-A in a dose- (Figure 1f ) and time-dependent manner ( Figure 1g ) with faster kinetics (Figure 1h ).
Az1 targets Aurora-A in the absence of ubiquitination Az1 is known to target its substrates, such as ODC, cyclinD1 and Smad1 for proteasomal degradation in the absence of ubiquitination. To address the nature of Az1-mediated degradation of Aurora-A, we used the A-box mutant of Aurora-A, which is resistant to cdh1-mediated degradation (Littlepage and Ruderman, 2002) . We have shown earlier that coexpression of Az1 and wild-type Aurora-A resulted in lower steady-state levels of Aurora-A protein. Similarly, when the cdh1-resistant A-box mutant of Aurora-A was coexpressed, Az1 was Figure 1 Az1 targets Aurora-A for proteasomal degradation. (a) Human epithelial cells from cervical carcinoma (HeLa) or Chinese hamster ovary (CHO) cells were cotransfected with HA-tagged Aurora-A and His-tagged Az1 at 1:9 ratio. A negative control has been included in which Az1 plasmid was replaced with the empty vector. Thirty-six hours post-transfection, the cells were harvested for western blot analysis to assess Aurora-A protein stability. Aurora-A and Az1 were detected using anti-HA and anti-Az1 antibodies, respectively. b-Tubulin was used as the loading control. (b) HeLa cells were transfected with either empty vector or His-tagged Az1. Thirty-six hours post-transfection, cell lysates were prepared for western blot analysis of the endogenous Aurora-A protein. Aurora-A and Az1 was detected using anti-IAK1 and anti-Az1 antibodies, respectively. CyclinD1 and cyclinB1 were detected as the positive and negative control, respectively. b-Tubulin was used as the loading control. (c) AT 2.1 cells were treated with 10 mM of putrescine for 24 h before harvest for western blot analysis of endogenous Aurora-A with anti-IAK1 antibody. CyclinD1 and cyclinA were detected with their respective antibodies. Induction of endogenous Az1 was followed with anti-Az1 antibody. b-Tubulin was used as the loading control. (d). HeLa cells were cotransfected with HA-tagged wild-type Aurora-A and His-tagged Az1 at 1:9 ratio. A negative control has been included in which Az1 plasmid was replaced with the empty vector. Twenty-four hours post-transfection, cells were treated with either DMSO or 20 mM MG132 or lactacystin for 16 h. The cells were harvested and analysed for Aurora-A and Az1 proteins. b-Tubulin was used as the loading control. (e) HeLa cells were transfected with His-tagged Az1 or empty vector. Twenty-four hours after transfection, cells were treated with either DMSO or 20 mM MG132 or lactacystin for another 16 h before analysing for the levels of endogenous Aurora-A and expression of Az1. b-Tubulin was detected as the loading control. (f) HA-tagged A-box mutant of Aurora-A and Az1 were individually synthesized by coupled in vitro transcription/translation in rabbit reticulocyte extracts. Aurora-A and Az1-containing lysates were mixed at different ratios in the presence of ATP-regenerating system and incubated for 2 h at 371C. Stability of Aurora-A was assessed by immunoblot analysis. Aurora-A and Az1 were detected using the anti-HA and anti-Az1 antibodies. (g) HA-tagged, A-box mutant of Aurora-A and Az1 were individually synthesized by coupled in vitro transcription/ translation in rabbit reticulocyte extracts. Aurora-A and Az1-containing extracts were mixed at 1:3 ratio and incubated with an ATPregenerating system at 371C. Samples were withdrawn at defined intervals and the stability of Aurora-A at different time points was assessed by immunoblot analysis. Az1 was detected using anti-Az1 antibody. (h) The Aurora-A levels (signal intensities) in the presence and absence of Az1 at different time points (immunoblot from Figure 1g ) were quantified using ImageJ software and plotted against time. The intensities at zero time points were assumed as 100%. Control (&) and Az1 ().
Antizyme1-dependent Aurora-A degradation SK Lim and G Gopalan able to decrease the steady-state levels of A-box mutant of Aurora-A also with similar efficacy (Figure 2a ). This suggested that Az1 targets Aurora-A for degradation in a manner distinct from cdh1. However, reversal of the effect of Az1 on the A-box mutant of Aurora-A by the proteasomal inhibitors MG132 and lactacystin demonstrated that the Az1 effect on A-box mutant is still proteasome-dependent. To test whether Az1-mediated degradation of Aurora-A can occur in the absence of prior ubiquitination, Az1 and Aurora-A were coexpressed in ts20-CHO, a temperature-sensitive cell line lacking Ub-activating enzyme E1 at the restrictive temperature and thus defective in the ubiquitination of proteasomal substrates (Strous et al., 1996) . Az1 was able to downregulate Aurora-A in the ts20-CHO cells even at the restrictive temperature (401C) as effectively as at the permissive temperature (301C) or in HeLa cells supporting the Ub-independent nature of degradation ( Figure 2b ). Similar Az1-mediated Ub-independent degradation of the ODC, the positive control substrate, could also be demonstrated at the restrictive temperature (Supplementary Figure 1b) . To address whether the Az1-mediated decrease in Aurora-A levels is due to increased turnover, a cycloheximide-chase experiment was performed. Az1 and Aurora-A were coexpressed in ts20-CHO cells and Aurora-A turnover in the presence of cycloheximide was followed at both permissive and nonpermissive temperatures (Figure 2c ). Faster turnover of Aurora-A in the presence of Az1 compared to the control could be observed at the nonpermissive temperature. In contrast, despite a decrease in the levels of Aurora-A in Az1-treated cells, the increased turnover of Aurora-A compared to the control is not evident at the permissive temperature. One of the possible explanations for this apparent lack of Az1 effect at the permissive temperature could be the high background turnover of Aurora-A in the control-and Az1-treated cells at 301C due to functional Ub-dependent pathway. Further, faster turnover of Az1 itself during the chase could also have contributed towards the slower kinetics. At the restrictive temperature, however, in the absence of ubiquitination, stabilization of Az1 levels and the Figure 2 Az1 targets Aurora-A in the absence of ubiquitination. (a) Human epithelial cells from cervical carcinoma (HeLa) cells were cotransfected with HA-tagged A-box mutant of Aurora-A and His-tagged Az1 at 1:9 ratio. Vector control has been included in which Az1 plasmid has been replaced with pCDNA3. Twenty-four hours post-transfection, cells were treated with either DMSO or 20 mM MG132 or lactacystin for 16 h. The cells were harvested and analysed for Aurora-A and Az1 using anti-HA and anti-Az1 antibodies. b-Tubulin was used as the loading control. (b) ts20-Chinese hamster ovary (CHO) cells were cotransfected with HA-tagged Aurora-A and either empty vector pCDNA3 or His-tagged Az1 at 1:9 ratio. Twenty-four hours post-transfection, cells were divided into two sets; one set was maintained at 301C, while the other set was incubated at 401C for 16 h. The cells were harvested and analysed for Aurora-A and Az1 using the anti-HA and anti-Az1 antibodies. b-Tubulin was used as the loading control. (c) ts20-CHO cells were cotransfected with HA-tagged Aurora-A and either pCDNA3 (vector) or His-tagged Az1 at 1:5 ratio. Eight hours post-transfection, one set of transfected cells was maintained at 301C while the other set was shifted to 401C. At 24 h post-transfection, both sets were treated with 50 mg/ml cycloheximide for the indicated times and harvested to assess Aurora-A protein turnover by immunoblot analysis. b-Tubulin was detected as the loading control. (d) ts20-CHO cells were cotransfected with FLAG-tagged p27 or mouse p53 and His-tagged Az1 at 1:9 ratio. Vector control has been included in which Az1 plasmid has been replaced with pCDNA3. Twenty-four hours posttransfection, cells were divided into two sets; one set was maintained at 301C while the other set was incubated at 401C for 16 h. The cells were harvested and analysed for p27, p53 and Az1 expression using anti-FLAG M2, anti-p53 and anti-Az1 antibodies, respectively. b-Tubulin was used as the loading control.
Antizyme1-dependent Aurora-A degradation SK Lim and G Gopalan absence of background Ub-dependent turnover of Aurora-A could have improved the kinetics of Az1-mediated degradation compared to the control. It is noteworthy that the levels of Az1 itself is stabilized at the nonpermissive temperature supporting the previous observation that Az is rapidly degraded through Ubdependent proteasomal activity (Gandre et al., 2002) . In view of the results presented in Figure 2c , it can be safely inferred that the Az1-mediated drop in Aurora-A levels is mainly due to degradation. Efficient degradation of Aurora-A by Az1 even at restrictive temperature indicated that the Az1-mediated degradation of Aurora-A is Ub-independent. In contrast, Az1 could not target cyclin-dependent kinase inhibitor, p27 or the tumor suppressor p53 for degradation at both temperatures (Figure 2d ), confirming the specificity of Az1-mediated Aurora-A degradation through this pathway.
Az1 interacts with Aurora-A in vivo
The results presented in the previous sections indicate that Az1 targets Aurora-A for proteasomal degradation through Ub-independent pathway. To further elucidate the role of Az1 as the targeting molecule, we investigated whether Az1 can interact with Aurora-A. Az1 and hemagglutinin (HA)-tagged Aurora-A were coexpressed in HeLa cells and pull-down assays were performed with antibodies against anti-HA tag antibody to pull down ectopically expressed Aurora-A. The result presented in Figure 3a shows that Az1 could be coprecipitated with Aurora-A, suggesting a possible interaction between Az1 and Aurora-A. To address the specificity of interaction, an interaction domain-mapping experiment was performed. To this end, deletion constructs lacking different regions of Aurora-A ( Figure 3b ) were coexpressed with Az1 and pull-down assays as described earlier were performed to map the regions of Aurora-A that interact with Az1. The results presented in Figure 3c show that a deletion of N-terminal 200 amino acids (DN600) and C-terminal 100 amino acids (DC300) does not interfere with the binding of Aurora-A with Az1. However, a further deletion of 100 amino acids from the C terminus (DC600) of Aurora-A completely abolished the interaction with Az1 suggesting that the region spanning residues 203-303 of Aurora-A is essential for its interaction with Az1.
Amino acid residues R 131 and G 145 of Az1 are essential for the degradation of Aurora-A It has been demonstrated that N terminus of ODC interacts with Az1 (Li and Coffino, 1993) and that the element contained within amino acids 130-145 of rat Az1 is essential for targeting ODC for proteasomal degradation (Chen et al., 2002) . To define whether this targeting domain of Az1 is involved in the targeting of Aurora-A for degradation, Az1 mutant, which lacks the N-terminal 120 amino acids (DN120-Az1) and Az1, which lacks only the amino acids 130-145 (D130-145-Az1) (Figure 4a ), were made and used to study in vivo degradation of Aurora-A in HeLa cells as described earlier. DN120-Az1 mutant targeted endogenous Aurora-A for degradation as effectively as the fulllength Az1. However, the D130-145-Az1 mutant, which lacks the 16-amino-acid region was markedly inferior in targeting Aurora-A protein for degradation (Figure 4b ). However, it is possible that the deletion of 16 aminoacid residues from the middle of the protein could have hampered the functionality of the protein as predicted before (Hoffman et al., 2005) . To rule out this possibility, a double mutant in which the residues R 131 and G 145 of human Az1 changed to aspartic acid (R131D/G145D) as described in Chen et al. (2002) was also generated and tested for its efficiency to target Aurora-A for degradation. It has been shown that simultaneous conversion of R 131 and A 145 in rat Az1 to aspartic acid totally abolishes its degradation capacity (Chen et al., 2002) . It should be noted that the arginine residue at 131 has been conserved between rat and human Az1, while the alanine at position 145 of rat Az1 has been replaced by glycine in human Az1. Despite this change, R131D/G145D double mutant of human Az1 showed decreased ability to target endogenous Aurora-A for degradation implying that these residues are essential for the degradation of Aurora-A also (Figure 4b ). Coexpression of Az1 mutants with Aurora-A in HeLa cells followed by immunoblot analysis revealed that the Az1 mutants lacking the element present within amino acids 130-145 of human Az1 are less effective in targeting exogenous Aurora-A for degradation (Figure 4c ). Taken together, these data support the notion that the amino-acid residues R 131 and G 145 of human Az1 are essential for targeting Aurora-A for degradation. To demonstrate further that the failure of D130-145-Az1 or R131D/G145D-Az1 to degrade Aurora-A protein did not arise due to their inability to interact with Aurora-A, pull-down assays were performed as described earlier. However, the results presented in Figure 4d , show that D130-145-Az1 and R131D/ G145D-Az1 were as efficient as the full-length Az1 in interacting with Aurora-A suggesting that the amino acid residues R 131 and G 145 of human Az1 are dispensable for the interaction, while essential for the degradation of Aurora-A.
Functional link between Az1 and AURKAIP1
We have shown earlier that the negative regulator AURKAIP1 facilitates degradation of Aurora-A through proteasome-dependent but Ub-independent pathway (Lim and Gopalan, 2007) . The results presented here suggest that Az1 might play the targeting role in the Ub-independent degradation of Aurora-A. To investigate whether there exists any functional link between AURKAIP1 and Az1, we exploited the Az inhibitor (AzI), a physiological regulator of the Az family (Mangold, 2006) . High AzI level downregulates Azmediated degradation of ODC as well as polyamine transport (Coffino, 2001) . To investigate whether Az1 plays a targeting role in AURKAIP1-mediated degradation of Aurora-A, AzI was expressed alone or with TR-AURKAIP1 (truncated AURKAIP1, a more potent form of AURKAIP1 in interacting and targeting Antizyme1-dependent Aurora-A degradation SK Lim and G Gopalan Aurora-A for degradation (Lim and Gopalan, 2007; Kiat et al., 2002) ) and Aurora-A stability in vivo was followed. The result presented in Figure 5a shows that the expression AzI alone had only a minimal effect on the stability of Aurora-A. However, it was able to counteract the effect of TR-AURKAIP1 on Aurora-A levels suggesting a role for Az1 in the AURKAIP1-mediated degradation of Aurora-A. To exclude any possibility that reversal of AURKAIP1-dependent Aurora-A degradation by AzI could be Az1-independent or to show a direct involvement of Az1 in this pathway, the Aurora-A deletion mutant DC600-Aurora-A, which is defective in interacting with Az1, was employed to study the degradation of Aurora-A in vivo. While full-length as well as other deletion constructs of Aurora-A, such as DN300, DN600 and DC300 could be targeted by TR-AURKAIP1, the DC600 deletion was resistant to TR-AURKAIP1-mediated degradation (Figure 5b) . Together, the results presented above suggest a role for Az1 in AURKAIP1-mediated degradation of Aurora-A. To define a functional link between Az1 and AURKAIP1, any interaction between AURKAIP1 and Az1 was studied by pull-down assays as described earlier. We could not detect any direct interaction between TR-AURKAIP1 and Az1 by pull-down assays (data not shown). However, Az1 was found to coprecipitate with AURKAIP1 when both Az1 and TR-AURKAIP1 were coexpressed with Aurora-A (Figure 5c ). This raised an intriguing possibility that Az1, TR-AURKAIP1 and Aurora-A could form a ternary complex. To explore further the existence of such a ternary complex in Aurora-A degradation, we studied the interaction between Az1 and Aurora-A in the presence and absence of TR-AURKAIP1. Az1 showed a basal affinity towards Aurora-A in the absence of TR-AURKAIP1. However, expression of TR-AUR-KAIP1 enhanced the binding of Az1 to Aurora-A significantly (Figure 5d ) suggesting that AURKAIP1 might function upstream of Az1 promoting its interaction with Aurora-A and facilitating the Az1-mediated proteasomal targeting of Aurora-A.
Discussion
Multiple regulators of Aurora-A kinase stability have been described recently (Mao et al., 2004; Yu et al., 2005) . Most of them target Aurora-A through Ubdependent and proteasome-dependent degradation pathway. In contrast, we identified a negative regulator His-tagged Az1 and either empty vector or FLAG-tagged Aurora-A at 1:1 ratio. Twenty-four hours post-transfection, cells were harvested for pull down with anti-FLAG antibody. The interacting Az1 was detected using the anti-Az1 antibody. Aurora-A was detected using the rabbit anti-FLAG antibody. (b) Comparison of the size and location of the deletions of all the Aurora-A deletion mutant proteins with full-length Aurora-A protein is presented. All of the Aurora-A variants contain a FLAG tag at the N terminus. The numbers within parentheses denote the nucleotides of Aurora-A cDNA and number 1 corresponds to the nucleotide A of the translational start ATG. The locations of KEN, A and D (D1, D2 and D3) boxes are indicated. (c) HeLa cells were cotransfected with His-tagged Az1 and FLAG-tagged wild-type or various deletion mutants of Aurora-A at 1:1 ratio. A negative vector control has been included in which Aurora-A plasmid was replaced with the empty vector. Twenty-four hours post-transfection, cells were harvested for pull down with mouse anti-Flag antibody. The interacting Az1 was detected using the rabbit anti-Az1 antibody and Aurora-A was detected using the rabbit anti-FLAG antibody.
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Aurora-A, AURKAIP1, which promotes degradation of Aurora-A in a proteasome-dependent but Ubindependent manner (Lim and Gopalan, 2007) and demonstrated for the first time that an Ub-independent pathway exists for Aurora-A degradation. To provide a mechanistic explanation regarding how AURKAIP1 targets Aurora-A to the proteasome machinery in the absence of ubiquitination, we investigated Az1, an established proteasome-targeting molecule in the Ub-independent pathway. We have shown here that Az1 can also target Aurora-A for degradation through proteasome-dependent but Ub-independent pathway. Both ectopic and polyamine-induced expression of Az1 can regulate the steady-state levels of Aurora-A. Increased turnover of Aurora-A in the presence of Az1 under both in vivo and in vitro conditions and the restoration of the steady-state levels of Aurora-A by proteasomal inhibitors supported the conclusion that Az1-mediated loss of Aurora-A is not an indirect effect of Az1 expression on Aurora-A levels but is proteasome-dependent degradation of Aurora-A. This is further supported by the direct interaction between Az1 and Aurora-A. Studies carried out using the A-box mutant of Aurora-A and temperature-sensitive cell line defective in ubiquitination at the restrictive temperature, suggest that Az1-mediated degradation of Aurora-A is mechanistically different from the cdh1-dependent degradation of Aurora-A and is Ub-independent. Despite the dismal knowledge we have on the significance and the physiological relevance of this alternative pathway, the growing list of protein substrates (Jin et al., 2003; Asher et al., 2005; Sdek et al., 2005) targeted to the proteasome in the absence of ubiquitination suggests that the Ub-independent route to the proteasome is as important as the Ub-dependent pathway. Az-mediated degradation of ODC, the first demonstrated prototype example of Ub-independent degradation, is essential for the maintenance of Thirty-six hours post-transfection, cells were harvested for western blot analysis of the endogenous Aurora-A. The Aurora-A and Az1 were detected using rabbit anti-IAK1 antibody and mouse anti-FLAG M2 antibody, respectively. b-Tubulin was used as the loading control. (c) HeLa cells were cotransfected with HA-tagged Aurora-A and either empty vector or wild-type or mutants of Az1 at 1:9 ratio. Thirty-six hours post-transfection, the transfected cells were harvested for western blot analysis of the protein stability of Aurora-A in the presence of overexpressed wild-type or mutant Az1. The Aurora-A and Az1 was detected using rabbit polyclonal anti-HA antibody and mouse anti-FLAG M2 antibody, respectively. b-Tubulin was used as the loading control. (d) HeLa cells were cotransfected with HA-tagged Aurora-A and either empty vector or FLAG-tagged wild-type/deletion mutant of Az1 at 1:1 ratio. Twenty-four hours post-transfection, the transfected cells were harvested for pull down with mouse anti-FLAG antibody. The interacting Aurora-A was detected using rabbit polyclonal anti-HA antibody. Both wild-type and deletion mutants of Az1 were detected using the rabbit anti-FLAG antibody.
Antizyme1-dependent Aurora-A degradation SK Lim and G Gopalan polyamine homeostasis in cells (Li and Coffino, 1992) . Az is capable of interacting with b-subunit HsN3 of proteasome and this interaction might facilitate targeting of its substrates to the proteasome (Lin et al., 2002) . It has been shown that the amino-acid residues R 131 and A 145 of rat Az1 are essential for the degradation of ODC (Chen et al., 2002) . Replacing these amino-acid residues with aspartic acid in human Az1 downregulated the ability of Az1 to target Aurora-A for degradation suggesting an important role for these residues in substrate degradation. This observation also increased the likelihood that these residues might be involved in the targeting of other substrates such as cyclinD1 and Smad1 (Lin et al., 2002; Newman et al., 2004) . It is yet to be shown whether these residues are indispensable for its interaction with the proteasome.
Higher levels of Az have been shown to be associated with decreased cell proliferation and hence Az has been considered as a tumor-suppressor (Iwata et al., 1999; Fong et al., 2003) . It is tempting to speculate that the negative regulation of the oncogenic Aurora-A could be one of the manifestations of its tumor-suppressor functions. Recently, cyclinD1, a crucial regulator of cell-cycle progression, has been described as the target of Az1. Az-mediated downregulation of cyclinD1 by proteasome was proposed as a mean to cease cell proliferation with G 1 arrest following Az upregulation (Newman et al., 2004) . Current knowledge on the expression and functions of Aurora-A does not support a role as a mediator of polyamine-induced G 1 arrest. However, Azs have evolved as a family with different functions other than polyamine metabolism and transport. Thirty-six hours post-transfection, transfected cells were harvested for western blot analysis to assess the stability of Aurora-A in the presence of TR-AURKAIP1 or AzI or both. Both Aurora-A and AzI were detected using the anti-HA antibody and TR-AURKAIP1 was detected using the anti-FLAG M2 antibody. b-Tubulin was used as the loading control. (b) ts20-CHO cells were cotransfected with HA-tagged TR-AURKAIP1 and FLAG-tagged wild-type or various deletion mutants of Aurora-A at 5:1 ratio. Thirty-six hours post-transfection, the transfected cells were harvested for western blot analysis to assess the stability of both wild-type and mutant Aurora-A, in the presence of TR-AURKAIP1. The Aurora-A and TR-AURKAIP1 was detected using the anti-FLAG M2 and anti-HA mouse monoclonal antibodies, respectively. b-Tubulin was used as the loading control. (c) HeLa cells were cotransfected with His-tagged Az1, HA-tagged Aurora-A and FLAG-tagged TR-AURKAIP1 at 1:1:1 ratio. A negative control has been included in which TR-AURKAIP1 plasmid was replaced with the empty vector. Twenty-four hours post-transfection, the transfected cells were harvested for immunoprecipitation with mouse anti-FLAG antibody. The interacting Az1 and Aurora-A were detected using the anti-Az1 and anti-HA antibodies, respectively. TR-AURKAIP1 was detected using the rabbit anti-FLAG antibody. (d) HeLa cells were cotransfected with His-tagged Az1 and FLAG-tagged Aurora-A at 1:1 ratio in the presence or absence of HAtagged TR-AURKAIP1. Twenty-four hours post-transfection, the transfected cells were harvested for immunoprecipitation with mouse anti-FLAG M2 antibody. The interacting Az1 was detected using the anti-Az1 antibody. Aurora-A and TR-AURKAIP1 were detected using the anti-FLAG and anti-HA antibodies, respectively.
It has been shown that treatment of cells with the rare polyamine, agmatine, suppresses proliferation by frame-shift induction of Az and attenuation of cellular polyamine levels (Satriano et al., 1998) . Moreover, HTC (rat liver hepatoma derived from Morris hepatoma) cells treated with agmatine showed a progressive accumulation of cells in G 2 /M phase of the cell cycle with no evident signs of apoptosis or necrosis (Gardini et al., 2003) . Against this background, it is tempting to speculate that Az-mediated Aurora-A degradation might be one of the multiple functions of Az on cell growth. The identification of the Aurora-A-binding proteins AURKAIP1 and Az1 as the regulators of the Ubindependent degradation of Aurora-A, poses the obvious question, whether there are any functional link between these two proteins. The results presented in this communication ( Figure 5 ) suggest that AURKAIP1 might act upstream of Az1 and promote its interaction with Aurora-A. Inhibition of Az1 functions by AzI or use of Aurora-A mutant defective in interacting with Az1 ameliorated AURKAIP1-dependent degradation of Aurora-A, predicting a mediator role for Az1 in this pathway. However, it is yet to be investigated whether Az could function independent of AURKAIP1 in the degradation of Aurora-A or despite its ability to target Aurora-A, Az1 should await for cue from AURKAIP1. In other words, the cellular context under which these pathways are operative is an intriguing future direction of investigation, which has the potential to unravel the mysteries of the physiology of AURKAIP1 as well as the significance of this alternative pathway of Aurora-A degradation. Based on the current knowledge on the mechanism of Az-mediated degradation where binding of Az to its protein substrate enhances the recognition and targeting of the substrate to the proteasome, we propose that AURKAIP1 functions upstream of Az1 promoting its interaction with Aurora-A and facilitates the Az1-mediated proteasomal targeting.
Materials and methods
Plasmids p27
Kip1 wt-pFLAG-N3 was obtained from Dr Christoph Geisen (The Burnham Institute, USA). FLAG-tagged mouse ODC-pCDNA3 was obtained from Dr Phillip Coffino (University of California, USA).
The cDNA encoding the wild-type human Az1 was obtained by RT-PCR (Promega Corp., Madison, WI, USA) of the RNA prepared from putrescine-treated HeLa cells using the primers: Az1-Forward (5 0 -gaggaattcatggtgaaatcctccctgcagcg-3 0 ) and Az1-Rev (5 0 -gcactcgagctactcctcctcctctcccgaa gactctctc-3 0 ). The human AzI cDNA was also obtained by RT-PCR of normal HeLa cell RNA using the primers: AzI-Forward (5 0 -gaattcatgaaaggatttattgatgatgc-3 0 ) and AzI-Rev (5 0 -ctcgagtta agcttcagcggaaaagctg-3 0 ). Various epitope tags (His, HA, FLAG) were added to the cDNAs by PCR and cloned into pCDNA3 (Invitrogen Corp., Carlsbad, CA, USA) and the bicistronic pIRES (Clontech Laboratories Inc., Mountain View, CA, USA) vectors. The frame-shift mutant of Az1 was generated by site-directed mutagenesis using the GeneEditor in vitro site-directed mutagenesis system (Promega) according to the manufacturer's protocol. The sequence of the mutagenic oligonucleotide used is 5 0 -gtggtgctccgatgcccctc-3 0 . All Az1 deletion mutants were constructed by PCR. DN120-AZ1 mutant cDNA was amplified using the designed primer pairs spanning the region of Az1 from amino-acid residues 121 to 229 (stop codon). FLAG tag was subsequently added to the N terminus by second PCR. The D130-145-Az1 mutant, an internal deletion of 16 amino acids from residue 130 to 145 was generated by nested PCR amplification. During this amplification, the 48-bp sequences corresponding to the region between amino-acid residues from 130-145 were replaced with sequences containing Sma1 and EcoR1 restriction sites without compromising the reading frame. FLAG-Az1 in pCDNA3 (full-length, frame-shifted mutant) was used as the PCR template. Two individual primary PCRs were set up; one reaction amplifying from 5 0 end of FLAG-Az1 cDNA (T7 primer) to amino-acid residue 129 (gene-specific primer with SmaI and EcoRI sites at the 5 0 end) and the second reaction amplifying from amino-acid residue 146 (gene-specific primer with SmaI and EcoRI sites at the 5 0 end) to 3 0 end of FLAGAz1 cDNA (SP6 primer). The two overlapping (SmaI and EcoRI regions) primary PCR products were gel purified and mixed in equal ratio and the D130-145 Az1 mutant cDNA was obtained by secondary PCR using the primer pair flanking the FLAG tag at the 5 0 end to the stop codon of Az1. The double mutant R131D/G145D was also generated using a two-step PCR. Desired mutations have been incorporated into the genespecific primers used for the primary PCR amplification. The sequence of the gene-specific primers used in the primary PCR are R131D-R: 5 0 -gtagaggctgccgccactcagcactgtgtcccagttaa tgcg-3 0 and G145D-F: 5 0 -ggcggcagcctctacatcgagatcc cggacggcg cgctgc-3 0 . FLAG-tagged wild-type Az1 in pCDNA3 was used as the template in two PCRs: one with T7 and R131D-R primers and the other with SP6 and G145D-F primers. The primary PCR products were gel purified, mixed and subjected to second PCR using the primer pair flanking the FLAG tag at the 5 0 end to the stop codon of Az1.
Antibodies
The specific antibodies used in this study are as follows: antib-tubulin (mouse monoclonal, 1:1000, Sigma-Aldrich Corp., St Louis, MO, USA), anti-cyclinA (rabbit polyclonal, 1:500, Santa Cruz Biotechnology Inc., CA, USA), anti-cyclinD1 (mouse monoclonal, 1:200, Santa Cruz), anti-cyclinB1 (rabbit polyclonal, 1:3000, Santa Cruz), anti-Az1 (rabbit polyclonal, 1:2000, a gift from John Mitchell (Northern Illinois University)), anti-FLAG M2 (mouse monoclonal, 1:2000, Stratagene, La Jolla, CA, USA), anti-FLAG (rabbit polyclonal, 1:3000, Sigma), anti-HA (mouse monoclonal, 1:2000, Sigma), anti-HA (rabbit polyclonal, 1:400, Santa Cruz), anti-His (mouse monoclonal, 1:1000, Sigma), Aurora-A (anti-IAK1, mouse monoclonal, 1:2000, BD Transduction Laboratories, San Jose, CA, USA) and anti-p53 (mouse monoclonal,1:2000, Santa Cruz). All horseradish peroxidase (HRP)-conjugated secondary antibodies (Pierce Biotechnology Inc., Rockford, IL, USA) were used at 1:8000 dilutions.
Cell culture, transfection and drug treatment The AT2.1 Dunning rat prostate carcinoma cells were obtained from Dr John T Isaacs (Baltimore, USA) and maintained at 371C in RPMI 1640 medium supplemented with 250 nM dexamethasone (Sigma). ts20 Chinese hamster cell line, which harbors the temperature-sensitive mutation in E1 Ub-activating enzyme, were obtained from Dr Ger J Strous (Utrecht, The Netherlands) and maintained at 301C in a-minimal essential medium medium supplemented with 4.5 g/l glucose. HeLa cells were maintained in RPMI 1640 medium. All mediums were supplemented with 10% heatinactivated fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine, 1 mM sodium pyruvate and 0.1 mM nonessential amino acids. For transient transfection, HeLa and ts20-CHO cells were plated at the density of 1 Â 10 6 and 2.5 Â 10 6 per 60 mm dish one day before transfection. On the day of transfection, the cells were transfected with 3 mg of plasmid DNA using the Lipofectamine 2000 (Invitrogen) according to the manufacturer's recommendations. Owing to very high level of transgene expression, the p27 kip1 -expressing construct was transfected with only 0.3 mg (1/10th of 3 mg normally used) of plasmid DNA.
For proteasomal inhibition, the cells were treated with 20 mM of MG132 (Sigma) or 20 mM lactacystin (Calbiochem, Darmstadt, Germany). For induction of endogenous Az expression, the AT2.1 cells were treated with 10 mM putrescine (Sigma) for 24 h.
Cell lysis, immunoblotting and immunoprecipitation
Harvested cells were washed twice with ice cold phosphatebuffered saline and lysed in 1 Â Laemmli buffer (25 mM Tris base, 192 mM glycine, 0.1% SDS), followed by pulsed sonication (Vibra Cell, Sonics & Materials Inc., Newtown, CT, USA; 5 Â 5 s with 10 s interval) on ice and subsequently cleared by centrifugation at 16 000 g for 10 min at 41C. The protein concentrations of the lysates were assayed using Bio-Rad Laboratories Inc. (Hercules, CA, USA) protein assay reagent (Pierce). Fifty to 100 mg proteins were separated on a 10 or 12% SDS-PAGE. The proteins were subsequently transferred to the nitrocellulose membrane (Pall Gelman Laboratory, East Hills, NY, USA). After blocking with 5% non-fat milk in Tris-buffered saline (TBS), the blots were incubated with various antibodies at their optimal dilutions overnight at 41C. The HRP-conjugated secondary antibodies (goat anti-rabbit HRP and goat anti-mouse HRP (Pierce)) were diluted in blocking buffer and incubated with the blot for 1 h at room temperature. The conjugated secondary antibodies were detected by SuperSignal Pico or Dura chemiluminescence (Pierce) detection system. To quantify the signal intensities in the immunoblots, ImageJ (version 1.36b) software (Rasband, WS, ImageJ, US National Institutes of Health, Bethesda, Maryland, USA; http://rsb.info.nih.gov/ij/, 1997-2006) was used.
For immunoprecipitation, cells were lysed for 15 min on ice in lysis buffer (1 Â TBS, 10% glycerol, 1% Nonidet P-40) containing protease inhibitors cocktail (Roche Diagnostics GmbH, Mannheim, Germany). The lysates were cleared by centrifugation at 16 000 g for 10 min at 41C. After measuring the protein concentration of the lysates as described above, the lysates were precleared by incubation with 50 ml of 50% slurry of protein G-agarose (Sigma) for 1 h at 41C. Antibodies were coupled to protein G-agarose by incubation for 1 h at 41C and the precleared lysates were mixed with antibody-coupled protein G-agarose and rotated for 2 h at 41C. Immune complexes were washed twice with buffer I (1 Â TBS, 10% glycerol, 0.5% Nonidet P-40, 1% bovine serum albumin) and twice with buffer II (1 Â TBS, 10% glycerol, 0.5% Nonidet P-40). The immune complexes were solubilized with the sample buffer and subjected to immunoblot analysis. Typically, 500 mg of lysate protein was used for immunoprecipitation experiments, while 50 mg of the total lysates were used for immunoblot analysis of the total lysates.
In vitro protein degradation assay A-box mutant of Aurora-A and Az1 were translated in vitro separately using reticulocyte-based TNT R T7 quick-coupled transcription/translation system (Promega). The Aurora-Aexpressing lysates were mixed with Az1 expressing lysates at different ratios and incubated in a assay buffer containing 50 mM Tris-HCl, pH 7.5; 2 mM dithiothreitol with 1 Â energy regeneration solution (Boston Biochem Inc., Cambridge, MA, USA) for up to 4 h at 371C. The reactions were stopped at different time points by addition of an equal volume of 2 Â SDS-PAGE sample buffer (0.24 M Tris, pH 6.8, 2.5% SDS, 20% glycerol, 8% b-mercaptoethanol) and boiled before analysis by SDS-PAGE.
